Biosion Secures Global Exclusive License Agreement with Aclaris Therapeutics for Two Promising Immunology Innovations
Biosion, Inc. (Biosion), a global biotechnology company in the R&D phase, unveiled a new exclusive licensing deal with Aclaris Therapeutics. This agreement grants Biosion universal rights (excluding Greater China) for BSI-045B, a potential pioneering, clinical-stage, innovative anti-TSLP monoclonal antibody, in […]